Innovation Zed and A Menarini Diagnostics Enter Commercial Agreement
Innovation Zed Ltd, an Irish medical technology company, and A. Menarini Diagnostics, a leading diagnostics company headquartered in Italy, and part of the Menarini Group, have announced an international partnership to commercialise the ‘InsulCheck Connect’ device developed by Innovation Zed.
‘InsulCheck Connect’ is an innovative insulin pen add-on device. It automatically collects essential usage data that informs insulin pen users of their injection history to assist them take control of their diabetes management. The ‘InsulCheck Connect’ device was specifically chosen to integrate within A. Menarini Diagnostics’ connected diabetes care platform.
With this agreement the two companies are forming a long-term partnership where A. Menarini Diagnostics will perform sales, marketing, training, and customer support, providing all necessary technical and clinical information for the correct use of the Insulin Pen ‘InsulCheck Connect’ device in regions around the globe including Europe.
Innovation Zed is headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin (UCD).
“We are very pleased with this announcement,” said Dean Minnock, Director of Business Development and Third-Party Relationships at Innovation Zed. “The relationships that A. Menarini Diagnostics has established with patients and healthcare providers in the diabetes community, and their extensive distribution expertise will positively position us to deliver to key international markets.”
“With this innovative insulin pen ‘InsulCheck Connect’ device, healthcare providers and patients will have a powerful tool to take under control the blood glucose levels and prevent diabetes complications,” said Fabio Piazzalunga, General Manager and Global Head, A. Menarini Diagnostics.
“This agreement is part of our strategy to develop a portfolio of fully integrated innovative products, allowing an enhanced management of diabetes for healthcare providers and an improved quality of life for patients.”
Dean Minnock added: “A.Menarini Diagnostics has established fantastic relationships with patients and healthcare providers and has extensive distribution expertise to effectively utilise the ‘InsulCheck Connect’ device to greatly empower the diabetes community.”
A. Menarini Diagnostics and Innovation Zed are also discussing terms to commercialise additional innovative systems to improve the quality of life for patients with diabetes.
